Rj. Vogel et V. Joish, The potential unintended economic consequences of the Medicine Equity and Drug Safety Act of 2000, CLIN THER, 23(4), 2001, pp. 629-643
Background: The Medicine Equity and Drug Safety (MEDS) Act of 2000 was pass
ed by Congress in October 2000 in response to the perception that US pharma
ceutical prices and expenditures were rising too quickly and that many peop
le could no longer afford their medication. The Act was terminated at the e
nd of December 2000 for lack of the congressionally required certification
by the Department of Health and Human Services of 2 key conditions written
into the law. Under the terms of the MEDS Act, pharmacists and wholesalers
would have been able to reimport lower-priced pharmaceuticals into the Unit
ed States from other countries.
Objective: In this article, we formulate an economic model as the basis for
determining the probable unintended effects of the MEDS Act and propose an
alternative policy that would achieve the objectives of the MEDS Act.
Methods: An economic model of parallel trade in the pharmaceutical industry
was used to demonstrate the likely effects of the MEDS Act.
Results: Although in most markets the effects of parallel trade would incre
ase economic efficiency, in the pharmaceutical industry parallel trade woul
d be detrimental to long-term economic efficiency. By encouraging parallel
trade into the United States, the Congress would, in effect, be introducing
pharmaceutical price controls from other countries that have price control
s. Parallel trade erodes price differences across countries and hence under
mines the most efficient pricing mechanism for paying for research and dev
elopment.
Conclusion: Although the MEDS Act was terminated, important policy lessons
can be learned for consideration in the creation of any similar future legi
slation designed to control pharmaceutical prices.